Author | Victor A. Levin, MD

Articles

Treating Anaplastic Oligodendrogliomas and WHO Grade 2 Gliomas: PCV or Temozolomide? The Case for PCV

April 15, 2015

In most cases, PCV chemotherapy will provide an edge in outcomes over TMZ for glioma patients, primarily because of the former regimen’s use of multiple drugs and their complementary interactions.

Treatment of Anaplastic Oligodendrogliomas: Should Resources Be Used to Codify the Old or to Create the New?

April 15, 2013

ByVictor A. Levin, MD

A turning point in therapy followed the observation that patients with AO tumors with chromosome 1p and 19q codeletion had better outcomes when treated with irradiation and PCV than did non-codeleted anaplastic oligodendroglioma patients.

Brain Tumors

April 01, 2005

ByEdward W. Soo, MD|Eugenio G. Galindo, MD|Victor A. Levin, MD

While the majority of primary central nervous system (CNS) tumors occur in patients over the age of 45 years, they are also the most prevalent solid neoplasms of childhood. About 16% of patients with brain tumors have a family history of cancer, and evidence points to chromosomal and genetic abnormalities. Magnetic resonance imaging (MRI) is superior to computed tomography (CT) in localizing tumors and in evaluating edema, hydrocephalus, and hemorrhage.